Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05672108 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Lung Chemoemobolization
A Phase 2 study of Sarcoma and Colon Cancer, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05672108: Recruiting Phase 2 study of Sarcoma and Colon Cancer, sponsored by City of Hope Medical Center.
NCT05672108 is a Phase 2 study of Sarcoma and Colon Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 30 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05672108, a Phase 2 study of Sarcoma and Colon Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.
Primary Outcome
Progression is determined using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. criteria, compared to the scan immediately prior to treatment of that territory, using the 2 largest measurable lesions per treated territory. Local progression-free survival will be estimated using the Kaplan-Meier method.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- DRUG Mitomycin
- PROCEDURE Transarterial Chemoembolization
- DRUG Ethiodized Oil
- DEVICE Tris-acryl Gelatin Microspheres
Study Locations (2)
California
- City of Hope Medical Center - Duarte
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-12 |
| Est. Completion | 2027-10-28 |
| Phase | Phase 2 |
What NCT05672108 shows while recruiting
NCT05672108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower).
The record links to 7 conditions, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05672108 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT05672108 about?
NCT05672108 is a clinical study titled "Phase II Trial of Lung Chemoemobolization". This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then bl...
What is the current status of trial NCT05672108?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-05-12. Estimated completion is 2027-10-28.
What conditions does trial NCT05672108 study?
This clinical trial studies the following conditions: Sarcoma, Colon Cancer, Lung Non-Small Cell Carcinoma, Pleural Neoplasm, Mediastinal Neoplasm.
What interventions are being tested in trial NCT05672108?
The interventions under investigation include: Computed Tomography (PROCEDURE), Mitomycin (DRUG), Transarterial Chemoembolization (PROCEDURE), Ethiodized Oil (DRUG), Tris-acryl Gelatin Microspheres (DEVICE).
Who is sponsoring clinical trial NCT05672108?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05672108 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05672108's enrollment target sits among peer trials
30 86th of 122 higher than 31 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy